Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.55 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395358 | 1.00 | MTNR1A (0.55) | MTNR1AMTNR1BADORA2ACHRM4MCL1 | |
| SCHEMBL3797385 | 0.93 | MTNR1A (0.47) | MTNR1AMTNR1BADORA2ACHRM4MCL1 | |
| SCHEMBL3391176 | 0.75 | MTNR1A (0.56) | MTNR1AMTNR1BADORA2ACHRM4MCL1 | |
| SCHEMBL6510668 | 0.75 | MTNR1A (0.56) | MTNR1AMTNR1BADORA2ACHRM4MCL1 | |
| SCHEMBL3391277 | 0.73 | MTNR1A (0.59) | MTNR1AMTNR1BADORA2ANPC1LMNA | |
| SCHEMBL1970413 | 0.73 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL1970411 | 0.73 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL3392202 | 0.72 | MTNR1A (0.55) | MTNR1AMTNR1BADORA2ACA1CA2 | |
| SCHEMBL3391271 | 0.72 | MTNR1A (0.55) | MTNR1AMTNR1BADORA2ACA1CA2 | |
| SCHEMBL3388818 | 0.72 | MTNR1A (0.62) | MTNR1AMTNR1BADORA2ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1370530-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002064565-A1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | MTNR1A 604/4885MTNR1B 448/4885ADORA2A 1717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.